Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith G Tolman

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Expert Opinion on Drug Safety|March 4, 2011
The safety of thiazolidinedionesKeith G Tolman
The American Journal of Cardiology|June 14, 2002
The liver and lovastatinKeith G Tolman
Clinics in Liver Disease|July 26, 2003
Hepatotoxicity of the thiazolidinedionesKeith G Tolman, Jane Chandramouli
Therapeutics and Clinical Risk Management|June 3, 2008
Treatment of non-alcoholic fatty liver diseaseKeith G Tolman, Anthony S Dalpiaz
American Journal of Therapeutics|March 16, 2005
The therapeutic use of acetaminophen in patients with liver diseaseGordon D Benson, Raymond S Koff, Keith G Tolman
Annals of Internal Medicine|December 22, 2004
Narrative review: hepatobiliary disease in type 2 diabetes mellitusKeith G Tolman, Vivian Fonseca, Meng H Tan, et al.
Drug Safety|August 13, 2009
Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the USKeith G Tolman, James W Freston, Stuart Kupfer, et al.
The American Journal of Gastroenterology|April 22, 2008
Abdominal bloating in employed adults: prevalence, risk factors, and association with other bowel disordersAshok K Tuteja, Nicholas J Talley, Sandra K Joos, et al.
Clinical Drug Investigation|December 14, 2006
Comparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteersKeith G Tolman, Jörg Täubel, Steven Warrington, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Expert Opinion on Drug Safety|March 4, 2011
The safety of thiazolidinedionesKeith G Tolman
The American Journal of Cardiology|June 14, 2002
The liver and lovastatinKeith G Tolman
Clinics in Liver Disease|July 26, 2003
Hepatotoxicity of the thiazolidinedionesKeith G Tolman, Jane Chandramouli
Therapeutics and Clinical Risk Management|June 3, 2008
Treatment of non-alcoholic fatty liver diseaseKeith G Tolman, Anthony S Dalpiaz
American Journal of Therapeutics|March 16, 2005
The therapeutic use of acetaminophen in patients with liver diseaseGordon D Benson, Raymond S Koff, Keith G Tolman
Annals of Internal Medicine|December 22, 2004
Narrative review: hepatobiliary disease in type 2 diabetes mellitusKeith G Tolman, Vivian Fonseca, Meng H Tan, et al.
Drug Safety|August 13, 2009
Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the USKeith G Tolman, James W Freston, Stuart Kupfer, et al.
The American Journal of Gastroenterology|April 22, 2008
Abdominal bloating in employed adults: prevalence, risk factors, and association with other bowel disordersAshok K Tuteja, Nicholas J Talley, Sandra K Joos, et al.
Clinical Drug Investigation|December 14, 2006
Comparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteersKeith G Tolman, Jörg Täubel, Steven Warrington, et al.
Pageof 1